Please login to the form below
Zalviso
This page shows the latest Zalviso news and features for those working in and with pharma, biotech and healthcare.
Grunenthal and AcelRx’s Zalviso approved in EU
Zalviso is a non-invasive, handheld system that allows hospital patients to self-dose with sublingual sufenatil microtablets. ... delivery. AcelRx developed Zalviso and entered into a commercial collaboration with Grunenthal at the end of 2013.
Latest news
-
Shire and Baxalta drugs among CHMP's latest recommendations
Grunenthal's Zalviso (sufentanil) for the treatment of post-operative pain. A hybrid medicine, Zalviso's application relied in part on the results of studies carried out with a reference product
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Grünenthal's relentless pursuit of relief
It is our passion to help these patients.”. It is also investing in New Technical Entities (NTEs) which include new formulations and devices, acquiring Zalviso, a combination of a medical device
-
Pharma deals in September 2015
PDL BioPharma is buying out the majority of the expected royalty stream from EU sales of AcelRX's phase III product, Zalviso for $65m. ... Royalty monetisation. 110. AcelRx Pharmaceuticals. PDL BioPharma. Zalviso sub-lingual formulation of sufentanil.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Account Director, Healthcare Communications
-
Salary TBC
Subscribe to our email news alerts
- GSK hires Merck KGaA exec to lead US pharma business
- Novartis chooses internal replacement for US pharma president role
- Moving annual total (MAT)
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Novartis chooses internal replacement for US pharma president role
- Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial
- A uniquely English genomic medicine service
- FDA rejects Sarepta’s new Duchenne drug over safety fears
- AZ claims first-in-class win for Farxiga in heart failure
- UK no longer measles-free as vaccination rates fall dramatically
- Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO
- Blended Intelligence
PMHub
Hayward Medical Communications
Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...
Latest intelligence
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
Quick links
Infographics
